Buy CLDX by Jul 19, 2026.

Barclays says it “can’t ignore” the faster than expected enrollment in the Phase 3 EMBARQ trial six months ahead of schedule and the Q4 readout of the study. At a minimum this speaks to the demand and enthusiasm for barzolvolimab, the analyst tells investors in a research note.